By leveraging mRNA technology—familiar from its use in Covid-19 vaccines, the team has found a way to expose the virus hiding ...

“It shows how protective these CCR5-delta 32 cells are. And — the most important part — if rebound occurs from the reservoir in this kind of transplant, HIV remission is still possible.

Unlike in previous cases, where the presence of the CCR5-delta 32 mutation seems to have played a decisive role in the HIV outcome, the study published shows that the Geneva patient's cells remain ...

possibly starting with gene editing to either cut some HIV reservoirs out of cells or replicate the Delta 32 mutation by deleting part of the CCR5 gene. This would then be followed up with a ...

The anonymous patient is the first to achieve long-term HIV remission — in this case approaching 6 years — after receiving a single CCR5 delta 32 mutation. Specifically, the patient received a ...

This case is different because the man received donor cells with only one copy (known as heterozygous) of a rare mutation called CCR5-delta-32 that disables a receptor HIV uses to enter T cells. Most ...

The team “began searching for donors with this rare genetic mutation known as the homozygous delta-32 CCR5 mutation, because we know that this mutation provides natural resistance to HIV ...

Unlike Brown and most of the others, the newest case involved a transplant from a heterozygous donor — someone with only one copy of the mutation, called CCR5-delta 32, which prevents HIV from ...

The mutation is called "homozygous CCR5 delta 32," it makes those with it immune to most kinds of HIV. It's currently estimated that only 2% of people in the world have this rare mutation.

Methodology: This meta-analysis comprised of published papers with over 10,000 individuals from whom CCR5-Delta 32 allele was successfully genotyped and recorded. The study review period was from 1984 ...